Innovation in CRC Research: Targeting SPACA6P-AS for Progression
Tianyi Ma1, Yinghu Jin1, Song Wang2
1Department of Colorectal Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Journal of Biochemical and Molecular Toxicology
|December 10, 2024
Summary
Elevated SPACA6P-AS expression promotes colorectal cancer (CRC) growth and is linked to poor survival. This long noncoding RNA acts as a competing endogenous RNA, targeting miR-339-5p to drive CRC cell proliferation, suggesting it as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Colorectal cancer (CRC) remains a significant global health challenge.
- Long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development.
- The specific function of SPACA6P-AS in CRC pathogenesis requires elucidation.
Purpose of the Study:
- To investigate the functional role of the long noncoding RNA SPACA6P-AS in colorectal cancer (CRC) biology.
- To determine the association between SPACA6P-AS expression levels and CRC progression and patient survival.
- To elucidate the molecular mechanism by which SPACA6P-AS influences CRC cell proliferation.
Main Methods:
- Analysis of SPACA6P-AS expression in colorectal cancer tissues.
- Knockdown experiments in colorectal cancer cell lines (in vitro).
- In vivo studies to assess tumor growth.
- Investigation of the competing endogenous RNA (ceRNA) activity of SPACA6P-AS involving miR-339-5p and the miR-339-5p/FAM167A signaling axis.
Main Results:
- SPACA6P-AS expression is elevated in colorectal cancer tissues and correlates with advanced disease stages and reduced overall survival.
- Knockdown of SPACA6P-AS inhibits colorectal cancer cell proliferation both in vitro and in vivo.
- SPACA6P-AS functions as a competing endogenous RNA, modulating miR-339-5p levels.
- The SPACA6P-AS/miR-339-5p/FAM167A axis promotes colorectal cancer cell proliferation.
Conclusions:
- SPACA6P-AS plays a crucial oncogenic role in colorectal cancer progression.
- SPACA6P-AS is a potential prognostic biomarker for colorectal cancer.
- SPACA6P-AS represents a promising therapeutic target for colorectal cancer treatment.
Related Concept Videos
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K